companiesCompany
NewLink Genetics (now Lumos Pharma)
aka Lumos Pharma
The Iowa biotech that ran the largest pancreatic cancer vaccine trial, IMPRESS, and the IDO inhibitor indoximod programme; it merged into Lumos Pharma in 2020.
Overview
NewLink Genetics developed the HyperAcute whole-cell vaccine platform, including algenpantucel-L for pancreatic cancer, and the IDO pathway inhibitor indoximod. After IMPRESS and PILLAR failed, the company merged with Lumos Pharma in 2020 and left oncology.
Headquarters
Ames, Iowa, United States, US
Scorecard
All companies#1001of 1003 companies, score -1
- modalities +2
- failures -3
0 approved, 0 in phase 3, 0 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Type
biotech
Stage
Public
Website
Founded
1999